Moderna's Stock Soars on Cancer Vaccine Breakthrough
Moderna's stock has experienced significant volatility following positive results from its melanoma vaccine trials in collaboration with Merck. Initially, shares surged nearly 177%, but later faced a 25% drop, wiping out $18 billion in market value. Despite this, optimism remains high regarding the potential of personalized mRNA treatments in cancer care.
Reports behind this story
Articles and publisher reports that informed this story.
How a Big Bet on Cancer Vaccines Brought Moderna Back From the Brink
After years of layoffs, cash burn and political attacks on its core technology, Moderna’s melanoma vaccine data notched the biotech company a much-needed win.
Moderna, Merck Cancer Vax Gives Hope
Scientists are on the cusp of fulfilling a decades-long quest: to use vaccines to teach the immune system to spot and destroy cancer cells. News that an mRNA cancer vaccine developed by Merck & Co. and Moderna Inc. kept melanoma from returning in a large, late-stage trial marks a critical next chapter for a technology beleaguered by post-pandemic political backlash and years of false starts before then. Bloomberg Opinion Columnist Lisa Jarvis writes "Moderna and Merck's Cancer Vaccine Is a Marvel." (Source: Bloomberg)
Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped
Doctors and patients are excited about the possible breakthrough, but some analysts believe there’s too much hype.
Moderna Stock Plunges 25%—Wiping Out $18 Billion After Historic Cancer Vaccine Breakthrough
The biotech giant posted positive trial results of a cancer vaccine, boosting shares at a record-setting pace before investors pulled back.
Moderna’s Shift to Cancer Company Lifts Stock Up 177%
The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else. A lab at Moderna’s headquarters in Cambridge, Mass., in 2024.
Moderna shares nearly triple on skin cancer vaccine success
Drugmaker’s melanoma shot developed with Merck delivers positive outcome in late-stage trial
Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring
The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.
Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means
A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.
Moderna’s 177% Surge Burns Shorts in ‘Painful’ $5.5 Billion Loss
A record surge in Moderna Inc.’s shares delivered a $5.5 billion blow to short sellers who had bet that the vaccine maker’s years-long slump would continue.
Moderna's share price nearly doubles on hopes of cancer treatment breakthrough
Optimism about a potential breakthrough in personalised cancer treatment has sent shares in Moderna soaring by nearly 100%. File image: iStock